6.995USD-0.64%Mkt Cap: 745.25M USDP/E: —Last update: 2026-05-26
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docet…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap745.25M USD
Enterprise Value-34.18M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-57.39M USD
Revenue/Share—
Last Price6.995 USD
Fiscal Year EndDec 2025
MR QuarterDec 2019
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS75955J4022
Valuation
P/E (Trailing)—
P/E (Forward)-17.59
PEG—
EV/EBITDA2.47
EV/Revenue—
P/S—
P/B6.11
EPS (TTM)-1.09
EPS (Forward)-0.41
52W Range
0.520087% of range8.000
52W High8.000 USD
52W Low0.5200 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-66.33%
ROA-61.05%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-45.79M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-1.04%
Net Debt-116.33M USD
Net Debt/EBITDA8.40
Balance Sheet
Debt/Equity0.10
Current Ratio80.21
Quick Ratio79.92
Book Value/Sh1.180 USD
Cash/Share10.22 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateSep 30, 2019
Splits
Last Split1:4
Split DateSep 30, 2019
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)12.80 USD
Target Range9.000 USD – 19.00 USD
# Analysts5
Ownership
Shares Out.104.89M
Float7.72M
Insiders2.90%
Institutions87.03%
Short Interest
Short Ratio3.9d
Short % Float5.42%
Short % Out.5.10%
Shares Short5.35M
Short (prev mo.)6.04M
Technical
SMA 506.972 (+0.3%)
SMA 2004.047 (+72.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)1.15M
Avg Vol (10d)1.14M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—